Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate
Timothy J. Poterucha(Columbia University Irving Medical Center), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Jan M. Griffin(Medical University of South Carolina), Sunil E. Saith(Columbia University Irving Medical Center), Andrew J. Einstein(NewYork–Presbyterian Hospital), Pierre Elias(Columbia University Irving Medical Center), Mona Kinkhabwala(Columbia University Irving Medical Center), Kathleen R. Flaherty(Memorial Sloan Kettering Cancer Center), Sabahat Bokhari(Boston University), Lynne L. Johnson(Providence College), Albert J. DeLuca(Columbia University Irving Medical Center), Adler Perotte(Columbia University)
Cited by 103
Related Papers
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2024|453
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|356
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
|JACC Heart Failure|2019|345
Cardiac Tumors: Clinical Presentation, Diagnosis, and Management
|Current Treatment Options in Oncology|2019|213